Look­ing for an ad­van­tage in the crowd­ed SMA space, Roche’s Genen­tech re­leas­es fresh Evrys­di da­ta

Roche has been look­ing for an edge in the SMA race, which so far has been dom­i­nat­ed by Bio­gen’s Spin­raza and No­var­tis’ Zol­gens­ma. And the megaphar­ma is hop­ing that some fresh da­ta could bet­ter de­fine that edge in Roche’s fa­vor.

Roche’s Genen­tech re­vealed Wednes­day that it has new two-year da­ta from the JEW­ELFISH study this week, eval­u­at­ing ris­diplam, mar­ket­ed as Evrys­di in the US, in type 1, 2 or 3 spinal mus­cu­lar at­ro­phy in pa­tients from 6 months to 60 years old. All pa­tients had been pre­vi­ous­ly treat­ed with oth­er ap­proved or in­ves­ti­ga­tion­al SMA-tar­get­ing ther­a­pies, such as Spin­raza and Zol­gens­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER